1
项与 OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd) 相关的临床试验Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
100 项与 OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd) 相关的临床结果
100 项与 OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd) 相关的转化医学
100 项与 OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd) 相关的专利(医药)
100 项与 OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd) 相关的药物交易